Centocor Exiting Diagnostics Business To Focus Exclusively on Therapeutics
This article was originally published in The Gray Sheet
Executive Summary
Centocor's commitment to its core pharmaceutical operation has been reinforced by the company's Oct. 30 announcement that it will sell its oncology diagnostics business to the Japanese firm Fujirebio for $37.5 mil.
You may also be interested in...
Lung Cancer Nucleic Acid Test Clinicals Under Development By DiagnoCure
DiagnoCure says its R&D collaboration with Compugen Ltd. will spur the launch of pivotal clinical studies evaluating a nucleic acid-based test for lung cancer by mid-2003
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.